

<i>(\$ in millions except where noted or per share data and percentages)</i>	Q2 19	FY 19	Q2 20
Total non-GAAP CF product revenues	<u>\$940</u>	<u>\$4.00B</u>	<u>\$1.52B</u>
TRIKAFTA	-	420	918
SYMDEKO/SYMKEVI	362	1.42B	172
ORKAMBI	316	1.18B	232
KALYDECO	262	991	203
Combined non-GAAP R&D and SG&A	<u>394</u>	<u>1.69B</u>	<u>467</u>
Non-GAAP operating income	413	1.79B	874
Non-GAAP operating margin	44%	45%	57%
Non-GAAP net income	327	1.39B	687
Non-GAAP net income per share - diluted	\$1.26	\$5.33	\$2.61
Cash, cash equivalents & marketable securities (period-end)	\$4.0B	\$3.8B	\$5.5B

Notes
 An explanation of non-GAAP financial measures and reconciliation of combined non-GAAP R&D and SG&A expense, non-GAAP net income and non-GAAP net income per share is included in the company's Q2 2020 press release dated July 30, 2020.

Reconciliation of non-GAAP operating income and non-GAAP operating margin to corresponding GAAP measures is included in the appendix of this presentation; totals may not add due to rounding.